These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Hellestrand KJ; Bexton RS; Nathan AW; Spurrell RA; Camm AJ Br Heart J; 1982 Aug; 48(2):140-8. PubMed ID: 7093083 [TBL] [Abstract][Full Text] [Related]
25. [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)]. Seipel L; Abendroth RR; Breithardt G Z Kardiol; 1981 Jul; 70(7):524-9. PubMed ID: 7269731 [TBL] [Abstract][Full Text] [Related]
26. Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction. Vik-Mo H; Ohm OJ; Lund-Johansen P Am J Cardiol; 1982 Nov; 50(5):1090-4. PubMed ID: 7137036 [TBL] [Abstract][Full Text] [Related]
27. [Flecainide: a new antiarrhythmic agent]. Leclercq JF; Coumel P Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1218-30. PubMed ID: 6418100 [TBL] [Abstract][Full Text] [Related]
28. Long-term antiarrhythmic therapy with flecainide. Meinertz T; Zehender MK; Geibel A; Treese N; Hofmann T; Kasper W; Pop T Am J Cardiol; 1984 Jul; 54(1):91-6. PubMed ID: 6741844 [TBL] [Abstract][Full Text] [Related]
29. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide. Pottage A Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279 [TBL] [Abstract][Full Text] [Related]
30. Flecainide versus quinidine: results of a multicenter trial. Hodges M; Salerno DM; Granrud G Am J Cardiol; 1984 Feb; 53(5):66B-71B. PubMed ID: 6364770 [TBL] [Abstract][Full Text] [Related]
31. [Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway]. Fauchier JP; Cosnay P; Rouesnel P; Moquet B; Bonnet P; Scala PJ; Demeyer JF Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():81-90. PubMed ID: 3938264 [TBL] [Abstract][Full Text] [Related]
32. The proarrhythmic effects of flecainide. Nathan AW; Hellestrand KJ; Bexton RS; Spurrell RA; Camm AJ Drugs; 1985; 29 Suppl 4():45-53. PubMed ID: 4006779 [TBL] [Abstract][Full Text] [Related]
33. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. Morganroth J; Anderson JL; Gentzkow GD J Am Coll Cardiol; 1986 Sep; 8(3):607-15. PubMed ID: 3745706 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death. Reid PR; Griffith LS; Platia EV; Ord SE Am J Cardiol; 1984 Feb; 53(5):108B-111B. PubMed ID: 6695814 [TBL] [Abstract][Full Text] [Related]
35. Lorcainide (R 15 889), a first review. Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313 [TBL] [Abstract][Full Text] [Related]
36. Use of flecainide acetate in the treatment of premature ventricular contractions. Abitbol H; Califano JE; Abate C; Beilis P; Castellanos H Am Heart J; 1983 Feb; 105(2):227-30. PubMed ID: 6823803 [TBL] [Abstract][Full Text] [Related]
37. Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation. Olsson SB; Edvardsson N Am Heart J; 1981 Nov; 102(5):864-71. PubMed ID: 7304394 [No Abstract] [Full Text] [Related]